Clyde Southwell, MD
Pulmonary Disease · Hendersonville, TNNPI 1346288966
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 641 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations.
Across 641 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$2K
- Boehringer Ingelheim$2K
- Insmed, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$740
- Sanofi$636
- plus $4K from 36 others
Across 71 payments — averaging $11,100 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$439K
- Genentech, Inc.$138K
- GSK$77K
- Hill-rom Company, Inc$63K
- Baxter Healthcare$31K
- Pfizer$21K
- plus $19K from 4 others
What the payments were for
- Food & beverage$12,35099%
- Education$1611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,511 in reported general payments places this provider in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 1,036 | $1,108,581 |
| OfevNintedanib Esylate | 54 | $625,828 |
| Dupixent PenDupilumab | 87 | $362,416 |
| Spiriva RespimatTiotropium Bromide | 313 | $293,547 |
| NucalaMepolizumab | 65 | $247,719 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 22 | $228,930 |
| Breo ElliptaFluticasone/Vilanterol | 288 | $173,614 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 181 | $171,614 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 212 | $160,824 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 163 | $107,652 |
| Fasenra PenBenralizumab | 17 | $96,559 |
| Dupixent SyringeDupilumab | 24 | $92,626 |
| XolairOmalizumab | 21 | $84,728 |
| Ambrisentan | 11 | $84,296 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,240 | $53,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,534 | $1,682,1381,644 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $1,606 | $1,080,199579 claims |
| Grifols USA, LLCProlastin C | $447 | $228,93022 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,752 | $209,666294 claims |
| PfizerEliquis | $13 | $22,27219 claims |
| Johnson & JohnsonXarelto | $44 | $19,84524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Hendersonville
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
- John SwisherKnoxville$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.